Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $214.6 million.

  • United Therapeutics' Other Non-Current Liabilities rose 4422.04% to $214.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.6 million, marking a year-over-year increase of 4422.04%. This contributed to the annual value of $181.9 million for FY2024, which is 13380.46% up from last year.
  • According to the latest figures from Q3 2025, United Therapeutics' Other Non-Current Liabilities is $214.6 million, which was up 4422.04% from $207.3 million recorded in Q2 2025.
  • United Therapeutics' 5-year Other Non-Current Liabilities high stood at $215.2 million for Q1 2025, and its period low was $67.4 million during Q3 2023.
  • For the 5-year period, United Therapeutics' Other Non-Current Liabilities averaged around $120.3 million, with its median value being $99.2 million (2021).
  • As far as peak fluctuations go, United Therapeutics' Other Non-Current Liabilities tumbled by 3487.92% in 2023, and later soared by 13380.46% in 2024.
  • Over the past 5 years, United Therapeutics' Other Non-Current Liabilities (Quarter) stood at $104.8 million in 2021, then fell by 0.19% to $104.6 million in 2022, then decreased by 25.62% to $77.8 million in 2023, then soared by 133.8% to $181.9 million in 2024, then grew by 17.98% to $214.6 million in 2025.
  • Its last three reported values are $214.6 million in Q3 2025, $207.3 million for Q2 2025, and $215.2 million during Q1 2025.